Ajit Narang works for Genentech, Inc., in South San Francisco, CA as a Sr. Scientist involved in the pharmaceutics and biopharmaceutics of small molecules in preclinical and early clinical development. of various dosage forms of small molecule drugs. He also serves as Adjunct Faculty at the Universities of Tennessee and Phoenix; Industrial Advisory Board member of Western Michigan University; a panel member of the Biopharmaceutics Technical Committee (BTC) of the Pharmaceutical Quality Research Institute (PQRI) in Arlington, VA; vice-Chair of the Formulation Design and Delivery (FDD) section of the American Association of Pharmaceutical Scientists (AAPS), and committee member of a Master’s Student at Campbell University, North Carolina.
Ajit earned his Ph.D. from the University of Tennessee in Memphis, Masters in Pharmaceutics from the Banaras Hindu University in India, and Bachelors in Pharmaceutical Sciences from the University of Delhi in India.
He has over 15 years of drug produt development experience working for Bristol-Myers Squibb, Co. (BMS) in New Jersey, Wockhardt Pharmaceuticals (ex-Morton Grove Pharmaceuticals) in Illinois, and Ranbaxy Research Labs in India in different capacities.
Ajit has contributed to several preclinical, clinical, and commercialized drug products including NDAs, ANDAs, and 505B2s. He is credited with over 40 peer-reviewed articles; 2 books; 7 patent applications; 20 invited talks; and 60 presentations at various scientific meetings.
His current research interests are translation from preclinical to clinical and commercial drug product design; incorporation of QbD elements in drug product development; and mechanistic understanding of the role of material properties on product performance.